Gain Contingency, Number of Defendants

No definition available.

Name:	pfe_GainContingencyNumberofDefendants
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2020

+ References

No definition available.

+ Details

Name:	pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2020
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Gain Contingency, Patents Allegedly Infringed upon, Number Due to Expire in December 2025

+ References

No definition available.

+ Details

Name:	pfe_GainContingencyPatentsAllegedlyInfringeduponNumberDuetoExpireinDecember2025
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity has allegedly infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity was found to have infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingencyPatentsFoundInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity was found not to have infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of another entity's patents that the entity has allegedly infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingencyPatentsAllegedlyInfringedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_ProductOrServiceAxis=pfe_PrecedexPremixMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=pfe_HospiraVersusAmnealPharmaceuticalsLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=pfe_HospiraVersusFreseniusMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=pfe_HospiraVersusParMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=pfe_BosulifMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=pfe_WyethVersusSunMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=pfe_ToviazMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=pfe_PfizerVersusMylanLaboratoriesandAccordHealthcareInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=pfe_PfizerVersusSeveralGenericManufacturersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=pfe_ToviazCompositionofmatterPatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=pfe_XeljanzMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=pfe_PfizerVersusMicroLabsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=pfe_PfizerVersusZydusMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=pfe_PfizerVersusPrinstonandBreckenridgeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=pfe_EliquisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_PatentInfringementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=pfe_BavencioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=pfe_PfizerVersusBMSE.R.SquibbSonsOnoPharmaceuticalandTasukuHonjoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationCaseAxis=pfe_PfizerVersusBreckenridgeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Actions In Which We Are The Plaintiff) (Details)		1 Months Ended														2 Months Ended	3 Months Ended
	Aug. 10, 2017 Patents	Oct. 31, 2017 Patents	Sep. 30, 2017 Patents	Jul. 31, 2017 Patents	Mar. 31, 2017 Patents	Feb. 28, 2017 Patents	Jan. 31, 2017 Patents	Aug. 31, 2016 Patents	Jul. 31, 2016 Patents	Jan. 31, 2016 Patents	Dec. 31, 2015 Patents	Jul. 31, 2015 Defendant	Jun. 30, 2015 Patents	Jan. 31, 2015 Patents	Jun. 30, 2013 Patents	Jul. 31, 2015 Defendant	Apr. 30, 2017 Patents Defendant
Precedex Premix [Member] \| Hospira Versus Amneal Pharmaceuticals LLC [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents not infringed upon													4
Precedex Premix [Member] \| Hospira Versus Fresenius [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents not infringed upon											4
Precedex Premix [Member] \| Hospira Versus Par [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents not infringed upon								4
Patent Infringement [Member] \| Bosulif [Member] \| Wyeth Versus Sun [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon			2
Patent Infringement [Member] \| Toviaz [Member] \| Pfizer Versus Mylan Laboratories Limited [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon									5	5				5
Number of patents infringed upon															5
Patent Infringement [Member] \| Toviaz [Member] \| Pfizer Versus Mylan Laboratories Limited [Member] \| Judicial Ruling [Member]
Gain Contingencies [Line Items]
Number of patents not infringed upon				5
Number of patents infringed upon	5					5	5
Patent Infringement [Member] \| Toviaz [Member] \| Pfizer Versus Several Generic Manufacturers [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of defendants \| Defendant												4
Patent Infringement [Member] \| Toviaz [Member] \| Pfizer Versus Several Generic Manufacturers [Member] \| Settled Litigation [Member]
Gain Contingencies [Line Items]
Number of defendants \| Defendant																4
Patent Infringement [Member] \| Toviaz Composition-of-matter Patents [Member] \| Pfizer Versus Mylan Laboratories Limited [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents infringed upon										3				3
Patent Infringement [Member] \| Toviaz Composition-of-matter Patents [Member] \| Pfizer Versus Several Generic Manufacturers [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents infringed upon															3
Patent Infringement [Member] \| Xeljanz [Member] \| Pfizer Versus MicroLabs [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon						3
Patent Infringement [Member] \| Xeljanz [Member] \| Pfizer Versus Zydus [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon					3
Patent Infringement [Member] \| Xeljanz [Member] \| Pfizer Versus Prinston and Breckenridge [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon					2
Patent Infringement [Member] \| Eliquis [Member] \| Pfizer and BMS Versus Several Generic Manufacturers [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon																	3
Number of defendants \| Defendant																	25
Patent Infringement [Member] \| Bavencio [Member] \| Pfizer Versus BMS, E.R. Squibb & Sons, Ono Pharmaceutical and Tasuku Honjo [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents				1
Subsequent Event [Member] \| Patent Infringement [Member] \| Xeljanz [Member] \| Pfizer Versus Breckenridge [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon		4
Number of patents due to expire in December 2020		3
Number or patents due to expire in December 2025		1